Study of your own CAR-T cells for hard-to-treat B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment made from your own immune cells (CAR-T cells) to help control relapsed or refractory B-ALL. It is designed for people whose disease has come back or not responded to prior therapy, and who have specific brain/spinal fluid and organ health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-ALL that has come back or did not respond to treatment
- You are between 13 and 65 years old
- Your spinal fluid test is clear or only mildly affected (no CNS-3, and CNS-2 has limited white blood cells)
- Your kidneys, liver, and heart function are strong enough for treatment
- You can do daily activities at a limited level (ECOG 0–2) and you have an expected survival of more than 3 months
- If you had a bone-marrow transplant from another person, it must be more than Day 100 ago and you must not have active graft-versus-host disease or require anti-GVHD drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a 'universal' CAR-T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to at least two prior treatments. The goal is to see if these special immune cells can safely find and destroy the cancer.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
Hear when a new Relapsed B Acute Lymphoblastic Leukaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.